Online inquiry

IVTScrip™ mRNA-Anti-SAA1, NEOD-001(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ12385MR)

This product GTTS-WQ12385MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets SAA1 gene. The antibody can be applied in AA amyloidosis research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Chimeric; Humanized
RefSeq NM_000331.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 6288
UniProt ID P0DJI8
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-SAA1, NEOD-001(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ12385MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6490MR IVTScrip™ mRNA-Anti-S, CT-P-59(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CT-P-59
GTTS-WQ12930MR IVTScrip™ mRNA-Anti-MUC1, PankoMab(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA PankoMab
GTTS-WQ15736MR IVTScrip™ mRNA-Anti-SEMA4D, VX-15(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA VX-15
GTTS-WQ14419MR IVTScrip™ mRNA-Anti-IL2RA, RO 24-7375(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA RO 24-7375
GTTS-WQ7912MR IVTScrip™ mRNA-Anti-CSF2, GSK3196165(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA GSK3196165
GTTS-WQ13530MR IVTScrip™ mRNA-Anti-MCAM, PRX-003(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA PRX-003
GTTS-WQ14456MR IVTScrip™ mRNA-Anti-IGF1R, RO4858696-000(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA RO4858696-000
GTTS-WQ7113MR IVTScrip™ mRNA-Anti-IL6&IL6R, FE 999301(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA FE 999301
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW